CLINICAL TRIALS PROFILE FOR TIOPRONIN

All Clinical Trials for tiopronin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	Food and Drug Administration (FDA)	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	University of Florida	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	University of Washington	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	E. Sander Connolly	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT02125721 ↗	Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	2012-06-01	The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.
NCT02125721 ↗	Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria	Completed	New York University School of Medicine	Phase 4	2012-06-01	The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Clinical Trial Conditions for tiopronin

Condition Name

Condition Name for tiopronin
Intervention	Trials
Cystinuria	3
Aneurysmal Subarachnoid Hemorrhage	1
Drug-Induced Liver Injury	1

Condition MeSH

Condition MeSH for tiopronin
Intervention	Trials
Cystinuria	3
Subarachnoid Hemorrhage	1
Hemorrhage	1
Wounds and Injuries	1

Clinical Trial Locations for tiopronin

Trials by Country

Trials by Country for tiopronin
Location	Trials
United States	10
China	4

Trials by US State

Trials by US State for tiopronin
Location	Trials
New York	4
Wisconsin	1
Rhode Island	1
Massachusetts	1
Alabama	1

Clinical Trial Progress for tiopronin

Clinical Trial Phase

Clinical Trial Phase for tiopronin
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for tiopronin
Clinical Trial Phase	Trials
Completed	4
Unknown status	1

Clinical Trial Sponsors for tiopronin

Sponsor Name

Sponsor Name for tiopronin
Sponsor	Trials
New York University School of Medicine	2
NYU Langone Health	2
Revive Therapeutics, Ltd.	1

Sponsor Type

Sponsor Type for tiopronin
Sponsor	Trials
Other	7
Industry	2
U.S. Fed	1

Clinical Trials Update, Market Analysis and Projection for TIOPRONIN

Last updated: May 2, 2026

What is tiopronin and how does it sit in today’s treatment landscape?

Tiopronin (a thiol drug; also known as alpha-mercaptopropionylglycine) is used in practice for cystinuria and cystine stone management, where it reduces cystine through thiol–disulfide exchange and improves solubility. The product category is typically treated as a long-cycle chronic therapy market tied to inherited disease prevalence, diagnosis rates, adherence, and stone recurrence economics.

Core commercial reality: tiopronin competes primarily against cystine-binding and urine-modifying approaches (including other thiol/chelators and alkalinization strategies), and it is also influenced by how often patients reach guideline-directed pharmacologic therapy after failed or insufficient response to hydration and urine alkalinization.

What do clinical trial updates indicate (by evidence in the public domain)?

No complete, authoritative clinical trial “update” for tiopronin can be issued here because the available input does not include trial identifiers, registry links, timelines, phase labels, or outcome datasets. A rigorous update requires at minimum: study registration numbers (e.g., NCT/EudraCT), dates, endpoints, and results status.

Constraint outcome: a complete and accurate clinical trials update cannot be produced from the information provided.

What is the market size anchor for tiopronin in cystinuria?

Market estimation for tiopronin must be grounded in:

• Cystinuria prevalence (diagnosed and treated fraction)
• Treatment share (tiopronin versus alternative cystine-binding strategies and alkalinization)
• Dosing and duration (long-term use in stone formers)
• Pricing by geography (generic versus branded status, reimbursement dynamics)

Because no prevalence rates, geographic coverage, current pricing, or product share data are provided in the input, a numerical market size estimate or revenue projection cannot be produced without risking inaccuracies.

Constraint outcome: no defensible numeric market size or forecast is possible from the current inputs.

How should demand be projected for tiopronin (model structure that investment teams use)?

Even without numeric inputs, tiopronin demand is projected using a structure tied to drivers below:

1. Incident diagnosis and treatment initiation

• People diagnosed with cystinuria who develop stones or are deemed at high risk start long-term pharmacologic therapy.
• Demand grows with diagnosis rate and early referral.

2. Treatment continuation and persistence

• Tiopronin use is chronic in stone-formers.
• Persistence depends on tolerability (notably nausea, proteinuria monitoring), lab surveillance burden, and perceived efficacy.

3. Switch and step-down dynamics

• Some patients may switch to alternative approaches (including other thiol agents in jurisdictions where available) if response is inadequate or intolerance occurs.
• Others maintain stable therapy for years.

4. Geography and reimbursement

• Access and out-of-pocket burden influence treated prevalence and adherence.
• Generic entry in key markets compresses unit revenue, even when patient numbers hold.

Constraint outcome: a numeric projection requires external market data not present in the provided material.

What is the competitive set and where does tiopronin typically win?

For cystinuria pharmacotherapy, the competitive set usually includes:

• Thiol drugs (where available in a given market)
• Urine alkalinization protocols (standard of care alongside pharmacotherapy)
• Specialist stone management pathways that affect when drug therapy is used

Tiopronin’s commercial position is shaped by:

• Availability as generic or branded in different regions
• Clinician familiarity and prescribing inertia for chronic cystine stone prevention
• Monitoring requirements that influence persistence and real-world continuation

Because no jurisdictional product list and no pricing/market share facts are provided in the input, a quantified competitive advantage cannot be stated.

What are the actionable investment indicators to track for tiopronin?

With no trial or market dataset available here, the only actionable path is to monitor indicators that directly map to tiopronin demand:

• Cystinuria diagnosis rates by country (referral pathways and genetic testing uptake)
• Stone clinic prescribing patterns (thiol selection and dose titration norms)
• Reimbursement changes and pharmacy formulary status (generic pricing, prior auth criteria)
• Safety and adherence signals in real-world records (persistence under monitoring schedules)
• Pipeline noise: new cystinuria drugs entering late-stage development that could shift prescribing away from tiopronin

Constraint outcome: no evidence-backed near-term timeline or quantified impact can be produced without sources.

What would a market projection table look like (framework, not numbers)?

A business-useful forecast table includes five elements:

Segment	Driver	KPI	Time horizon	Output
Diagnosed cystinuria patients	diagnosis uptake	treated prevalence	1-3 years	patient starts
Stone-former proportion	clinical risk stratification	recurrence history	1-3 years	eligible population
Therapy persistence	tolerability and monitoring	% continuous therapy	3-5 years	on-treatment pool
Unit revenue	pricing and reimbursement	average net price	1-5 years	revenue per patient
Switch behavior	alternative thiol usage	persistence after switch	3-5 years	churn-adjusted demand

Constraint outcome: the table cannot be populated with defensible numeric projections without market and pricing inputs.

Key Takeaways

• Tiopronin is a long-cycle chronic therapy tied to cystinuria and cystine stone prevention.
• A complete, accurate clinical trials update and a numeric market analysis cannot be produced from the information provided because registry identifiers, outcome data, and market/pricing inputs are not included.
• Investment-grade forecasting depends on diagnosed treated prevalence, persistence, unit net price, and switch behavior by geography.

FAQs

1) Is tiopronin a high-growth market?

It is typically a stable, chronic-demand market driven by diagnosed cystinuria prevalence and persistence rather than short-duration “peak and fade” dynamics.

2) What most strongly drives tiopronin revenue in real life?

Treated patient population (diagnosis and initiation) plus persistence under monitoring, adjusted for unit net price by geography and generic status.

3) Do clinical trial updates materially change the tiopronin outlook?

They can, but only if there are phase-appropriate efficacy and safety readouts that change prescribing guidelines or payer coverage. Without trial identifiers and outcomes, no change can be quantified.

4) What competitive factors matter most?

Thiols availability by region, clinician familiarity, and tolerability profiles that affect persistence. Non-drug standards (hydration, urine alkalinization) also influence when and whether tiopronin is used.

5) How should investors time diligence?

Focus diligence on treated prevalence trends, formulary/reimbursement changes, and any late-stage cystinuria pipeline readouts that could shift thiol selection away from tiopronin.

---

References

[1] No citable sources were provided in the prompt.